Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
FGFR2 amp FGFR2 mut Debio 1347 cervical adenocarcinoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT01101451 Phase III Cisplatin Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery Recruiting
NCT02257528 Phase II Nivolumab Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer Active, not recruiting
NCT02348398 Phase II Pazopanib + Topotecan Phase II Study of Pazopanib and Topotecan in Cervical Cancer Withdrawn
NCT02466971 Phase III Cisplatin Cisplatin + Triapine Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers Recruiting
NCT02584478 Phase Ib/II Anlotinib + Carboplatin + Paclitaxel Phase 1/2a Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) Recruiting
NCT02595879 Phase I Cisplatin + Triapine Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer Recruiting
NCT02834013 Phase 0 Ipilimumab + Nivolumab Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting
NCT02853604 Phase III ADXS11-001 Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer (AIM2CERV) Active, not recruiting
NCT03108495 Phase II LN-145 Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma Recruiting
NCT03367871 Phase II Cisplatin + Paclitaxel + Pembrolizumab Combination Pembrolizumab, Paclitaxel and Cisplatin in Patients With Cervical Cancer Recruiting
NCT03438396 Phase II Tisotumab Vedotin A Trial of Tisotumab Vedotin in Cervical Cancer Active, not recruiting
NCT03495882 Phase Ib/II Balstilimab + Zalifrelimab Subjects With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical) Active, not recruiting
NCT03635567 Phase III Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Cisplatin + Paclitaxel Carboplatin + Paclitaxel Cisplatin + Paclitaxel Cisplatin + Paclitaxel + Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab Bevacizumab + Cisplatin + Paclitaxel + Pembrolizumab Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826) Active, not recruiting
NCT03644342 Phase Ib/II Niraparib Study of Niraparib With Radiotherapy for Treatment of Metastatic Invasive Carcinoma of the Cervix (NIVIX) Recruiting
NCT03738228 Phase I Atezolizumab + Cisplatin Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer Suspended
NCT03786081 Phase Ib/II Bevacizumab + Tisotumab Vedotin Carboplatin + Tisotumab Vedotin Pembrolizumab + Tisotumab Vedotin Safety and Efficacy of Tisotumab Vedotin in Combination With Other Cancer Agents in Subjects With Cervical Cancer Recruiting
NCT03830866 Phase III Durvalumab Cisplatin + Durvalumab Carboplatin + Durvalumab Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA) (CALLA) Recruiting
NCT03894215 Phase II Balstilimab Balstilimab + Zalifrelimab Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer Recruiting
NCT04221945 Phase III Cisplatin + Pembrolizumab Cisplatin Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11) Recruiting
NCT04230954 Phase II Cabozantinib + Pembrolizumab Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer Recruiting
NCT04246489 Phase II M7824 Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer Recruiting
NCT04300647 Phase II Atezolizumab Atezolizumab + MTIG7192A A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer (SKYSCRAPER-04) Recruiting
NCT04381650 Phase Ib/II Pembrolizumab + TAK-981 A Safety and Efficacy Study of TAK-981 Plus Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors Recruiting
NCT04551950 Phase I Bevacizumab + Carboplatin + M7824 + Paclitaxel Bevacizumab + Cisplatin + M7824 + Paclitaxel Cisplatin + M7824 + Paclitaxel Cisplatin + M7824 Carboplatin + M7824 + Paclitaxel Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTRAPID 046) Not yet recruiting